Experimental drug aims to stop bleeding in patients on blood thinners
NCT ID NCT03172910
Summary
This study tested whether a new drug called ciraparantag could safely and effectively reverse the effects of the blood thinner rivaroxaban. Healthy volunteers aged 50-75 took rivaroxaban for three days, then received either ciraparantag or a placebo to see how quickly their blood's ability to clot returned to normal. The goal was to find a treatment for emergency situations where rapid reversal of blood thinners is needed to control bleeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Frontage Clinical Services Inc.
Secaucus, New Jersey, 07094, United States
Conditions
Explore the condition pages connected to this study.